Overview

Fertility-sparing Management Using High-dose Oral Progestin in Young Women With Endometrial Cancer

Status:
Not yet recruiting
Trial end date:
2022-11-30
Target enrollment:
Participant gender:
Summary
This registry aims to evaluate the efficacy of using high-dose oral progestin in young women with stage I endometrial adenocarcinoma with grade 2 differentiation or superficial myometrial invasion as a fertility-sparing management.
Phase:
Phase 2
Details
Lead Sponsor:
Asan Medical Center
Collaborator:
Korean Gynecologic Oncology Group
Treatments:
Medroxyprogesterone
Medroxyprogesterone Acetate
Progestins